ClinicalTrials.gg
Active, not recruitingNCT07243574Updated Oct 15, 2026

Night Owl Sleep Study: The Effect of Sleep on Fecal Microbiota

An interventional study of Increase sleep by 90 minutes and Decrease sleep by 90 minutes in Sleep, sponsored by Danisco. Active, not recruiting at 3 sites in United States. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Danisco (part of International Flavors & Fragrances Inc.) · Not applicable, Interventional, and Other

How we know

Updated Oct 15, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Non-randomized
Ages
20 Years to 40 Years
Sex
All
01

Study summary

The goal of this clinical trial is to assess differences in the fecal microbiota and metabolome associated with insufficient and sufficient sleep, and to evaluate the response and recovery of the microbiota to changes in participant sleep profiles.

Researchers will compare the effect of sleep intervention on both insufficient and sufficient sleepers to identify differences in fecal microbiota structure and function between cohorts during habitual sleep and during the sleep alteration intervention period..

Participants will be assigned to one of two cohorts based on their current sleep habits. Cohort 1 are participants who have insufficient sleep at baseline; this cohort will be assigned to spend 1.5 hours more in bed per night. Cohort 2 are participants who have sufficient sleep at baseline; this cohort will be assigned to spend 1.5 hours less in bed per night. The sleep intervention lasts for 14 days.

02

Conditions studied

  • Sleep
03

In context

Lead sponsor

Danisco is the lead sponsor of 24 studies on the registry; 2 are open to participants now.

First submitted after Danisco became part of International Flavors & Fragrances Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men between 20 - 50 years of age and pre-menopausal women between 20 - 45 years of age (inclusive).
  2. Consistent schedule during daytime hours.
  3. 18.5 - 35 kg/m2 (inclusive).
  4. Good physical and mental health as established by self-reported medical history.
  5. Willingness to maintain and record their general habits, eating, and activity/exercise pattern for the study period.
  6. Willingness to maintain and record the same time in bed they have during the workdays throughout the habitual workday sleep period.
  7. Able to alter sleeping time during the study intervention period as instructed.
  8. Willingness to maintain typical sleep hygiene patterns (e.g. sleep location, temperature, environment).
  9. Willingness to maintain their current pattern of alcohol consumption for the duration of the study.
  10. Willing and able to participate fully in all aspects of the study and complete all study procedures, including providing signed .
  11. Completes all study procedures during the 14-day screening period to be eligible for the cohort specific criteria based on the sleep data collected during the screening period.
  12. Has regular bowel habits with bowel movements on at least 5 days a week.
  13. Pittsburgh Sleep Quality Index (PSQI) score ≤10. Note: If PSQI score is between 8 and 10, PI discretion needed to confirm eligibility based on self-report screening diaries and health \& lifestyle questionnaire.

Cohort specific inclusion criteria:

Cohort 1 (Insufficient Sleep)

Participants must meet all general inclusion criteria PLUS:

  1. Sleep, on average, 5-7 hours per night on workdays, verified via participant self report during the screening period. Note: Oura ring data from the run-in period will be reviewed to confirm cohort based on PI/Sponsor discretion.
  2. Average KSS Score of 6-10 on workdays during the screening period. Note: Use standard rounding rules for averages with decimal places.

Cohort 2 (Sufficient Sleep)

Participants must meet all general inclusion criteria PLUS:

  1. Sleep, on average, 7-9 hours per night on workdays, verified via participant self-report during the screening period. Note: Oura ring data from the run-in period will be reviewed to confirm cohort based on PI/Sponsor discretion.
  2. Average KSS Score of 1-5 on workdays during screening period. Note: Use standard rounding rules for averages with decimal places.

Exclusion criteria

Exclusion:

  1. Any current diagnosed or self-reported sleep disorder, including but not limited to sleep apnea, habitual snoring (defined as loud, persistent snoring 3 or more nights per week), insomnia, narcolepsy, and parasomnias.
  2. Any current diagnosed or self-reported gastrointestinal disorder, including Crohn's disease, ulcerative colitis, celiac disease, IBS, or functional bowel disorder or chronic heart burn.
  3. Regularly wakes up during the night 5 or more times per night for a cumulative amount of 30 minutes as observed via self-report during the screening period, per Principal Investigator (PI) discretion.
  4. Currently taking medications (including over-the-counter medications) or dietary supplements that, in the investigator's opinion, may affect the participants' microbiome or sleep.
  5. Have taken in the last 3 months medications (including over-the-counter medications) or dietary supplements that, in the investigator's opinion, may affect the participants' microbiome or sleep.
  6. Neurodegenerative diseases (including multiple sclerosis, Parkinson's disease, Alzheimer's disease, dementia).
  7. Recent history (current use or within the past 1 month) of smoking, vaping or other use of nicotine-containing products.
  8. Recent history (past year) of alcohol abuse or dependence. Defined as regularly drinking more than 12 drinks for females and more than 20 drinks for males per week and based on PI discretion.
  9. Drug abuse or dependence, including consistent recreational substance use such as marijuana.
  10. Binge drinking behavior, defined as 4 or more alcoholic drinks for women or 5 or more alcoholic drinks for men in one sitting on 2 or more occasions, within the past 1 month with final decision per PI discretion.
  11. Diagnosed neuropsychiatric disorders or symptoms possibly affecting sleep (generalized anxiety disorder (GAD), major depressive disorder (MDD), bipolar disorder, schizophrenia)
  12. Any use of systemic antibiotics in the past 3 months. Topical or targeted antibiotic use (eye drop, ear drop) are allowed.
  13. Any use of probiotic supplements in the past 2 weeks.
  14. Any use of proton pump inhibitors (PPIs) in the past 2 weeks.
  15. Pregnant or breastfeeding or planning to become pregnant.
  16. Personal life situation causing stress or challenges in sleep (eg. caretaker required to wake up during sleep, major change in personal life). Note: Life situations causing stress or challenges in sleep that are considered short-term, per PI discretion, may be considered for re-screening 4 weeks after the life situation has resolved, meaning it is no longer causing stress or challenges in sleep.
  17. Planned overnight or cross time zone travel during the study.
  18. Females experiencing perimenopausal or menopausal symptoms, or those who have been diagnosed as perimenopausal or menopausal by a physician.
  19. Any diagnosed condition or undiagnosed symptom which disrupts sleep, including, but not limited to, hyperthyroidism, night sweats, restless legs, or poorly controlled allergic rhinitis.
  20. Extreme chronotypes for Cohort 2 (Sufficient Sleep); those that regularly go to sleep prior to 08:00 pm or after 2:30 am on 3 or more nights a week.
  21. Extreme chronotypes for Cohort 1 (Insufficient Sleep); those that regularly go to sleep prior to 08:00 pm on 3 or more nights a week.
  22. Varying work schedule and/or shift workers who work overnight shifts (e.g. 3rd shift, working late night to early morning hours)
  23. Any other personal or medical condition that the investigator believes may bias or confound the results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Active comparator
    Cohort 1

    Cohort 1 are participants who have insufficient sleep at baseline; this cohort will be assigned to spend 1.5 hours more in bed per night.

    Behavioral: Increase sleep by 90 minutes

  • Active comparator
    Cohort 2

    Cohort 2 are participants who have sufficient sleep at baseline; this cohort will be assigned to spend 1.5 hours less in bed per night.

    Behavioral: Decrease sleep by 90 minutes

Interventions

  • BehavioralIncrease sleep by 90 minutes

    For 14 days, participants will increase their nightly sleep by 90 minutes.

  • BehavioralDecrease sleep by 90 minutes

    For 14 days, participants will decrease their nightly sleep by 90 minutes.

06

What researchers measure

Primary outcomes

  1. Differences in the fecal microbiota of individuals with sufficient and insufficient sleep.

    Measure changes in microbial abundance and diversity from baseline to the end of the study in those individuals who have sufficient sleep compared to those with insufficient sleep. This is comparing the sufficient sleep group to the insufficient sleep group across all study periods.

    Time frame: From Day 1 to Day 28

  2. To evaluate the response of the microbiota to changes in participant sleep duration.

    Measure changes in gut microbiota within the individual during times of sufficient sleep compared to when they are getting insufficient sleep.This is measuring the change within individual participants before the intervention and after.

    Time frame: From Day 1 to Day 28

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Nov 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Nov 24, 2025
StartActual
Sep 17, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Feb 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07243574
Lead sponsor
Danisco
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Sep 17, 2025
Primary completion
Nov 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion